Articles On Imugene (ASX:IMU)

“Imugene receiving this patent grant for the CF33 family of oncolytic viruses from the Japanese patent office is a crucial step forward and is the first of many expected patent grants from multiple countries," says CEO.

On 28th January 2022, the stock market in Australia ended in green. On the same day, ASX 20 rose by 2.45% and ASX MIDCAP50 has witnessed a rise of 1.82%. Also, ASX 100 rose by 2.12% as well as ASX 200 has encountered a rise of 2.19%. Dat...

Today, the S&P/ASX 200 Index (ASX: XJO) fought back against the selling pressure throughout the day to finish in the green. At the end of trade, the benchmark index was 2.19% higher at 6,988.1 points. In stark contrast to the rest of...

We’ve all gone a little bit crackers on Friday – or as the Kiwi’s like to say in French – un peu fou de fafa. Trading volumes – unless I’m drunk – are about double what they usually are. Wait… 95% above the 20-day moving average. It’s a lot...

Key Points Imugene shares rocket on back of new supply agreement with Roche Clinical trial of PD1-Vaxx will be combined with an immune checkpoint inhibitor The deal is expected to last up to five years The Imugene Limited (ASX: IMU) sha...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is rebounding strongly from recent declines. At the time of writing, the benchmark index is up 2.3% to 6,994.7 points. Four ASX shares that are climbing more than most today are list...

28 Jan 2022 - Bio-tech company Imugene (ASX:IMU) has made two announcements today regarding its HER-Vaxx and PD1-Vaxx.

Key points Imugene share price soared 5% on the back of European patent approval This is further intellectual protection for the company’s HER-Vaxx immunotherapy Today’s news follows recent South Korean patent award Imugene Limited (ASX...

Clinical stage immuno-oncology company Imugene (IMU) granted a European patent for its HER-Vaxx immunotherapy technology which is designed to treat cancer The patent entitled “A Vaccine Composition and Uses Thereof” protects the method of...

The patent protects the company's gastric cancer treatment, HER-Vaxx, for method of composition and method of use in the important European market until 2036. 

ASX is up in a wild session that has seen big swings. Ramelius tumbles as WA's closed border hits guidance, Newcrest falls on production update and Imugene rallies.

Highlights Australian shares fell 0.5%, or 36.3 points to 7139.5 today. Investing sentiment today was weighed down by losses across the materials and technology sectors. Investors await an array of economic updates and meetings this w...

Fears of a market meltdown subsided early today as the ASX 200 fell by just 0.5%, lifted by the bounce back in US stock futures in Asian trading. A rush of US earnings reports in the next few days, along with the two-day Federal Reserve mee...

Highlights Today, the ASX 200 closed sharply lower; the broad-based decline was led by the materials and energy sectors. Asian share markets and US futures also fell. The global crypto market cap tanked more than 5%. Today, the AS...

ASX health stocks (XHJ index) are down .99% today but faring better than the ASX 200 which has fallen sharply at 1.5%. The HeraMED (ASX:HMD) share price rallied 6.9% to 31 cents in early morning trade before settling ~3.45% as the company a...

The company thanked Dr Laeufle for her role in advancing Imugene's clinical activities - it is now in the final stages of recruiting a new immuno-oncology expert to assume the role of chief medical officer.

Highlights The ASX 200 closed 1% lower today, thanks to a sell-off in US stocks overnight. Investors withdrew from risk assets; government bond yields scaled up. Asian stocks also traded in the red zone. The global cryptocurrency mar...

A risk-off down-shift on global markets pushed Australian shares to their weakest close of the year as spikes in energy prices and lending rates added to investor worries. The S&P/ASX 200 sank 76 points or 1.03 per cent to 7333. The...

On 18th January 2022, the equity market of Australia closed in red. On the same day, ASX Midcap50 rose by 0.04% and ASX 200 was down by 0.11%. ASX All Ordinaries moved down by 0.05% to 7,735.80. On the same day, ASX 100 also encountered a f...

Today, the S&P/ASX 200 Index (ASX: XJO) slipped to the downside after starting off in the green. At the end of the session, the benchmark index finished 0.11% lower at 7,408.8 points. Investors were split on how to view the Aussie sha...

Local markets were somewhat directionless today as Wall Street took time out for the Martin Luther King Jr holiday overnight. The ASX 200 failed to maintain early momentum, finishing the day in the red down by 0.11%. The Mining index was hi...

Highlights The ASX 200 added 48.8 points and closed at 7438.9 today, thanks to a strong session by energy and technology stocks. Asian stocks witnessed a rebound, same as their American peers after Jerome Powell reassured investors the...

Today, the S&P/ASX 200 Index (ASX: XJO) pulled higher in a similar fashion to Wall Street’s showing last night. At the end of the session, the benchmark index finished 0.66% higher at 7,438.9 points. Pleasingly, most of the sectors ac...

The ASX 200 was up 0.59% today after a flat start to the week. Both US and EU stocks rose after US Federal Reserve Chairman Jerome Powell reiterated the central banks efforts to corral inflation before the Senate Banking Committee. Powell s...

The money will support the immuno-oncology company’s commercial and clinical milestones, several of which it has ticked off in the last few weeks.

Highlights  The ASX 200 fell 2.7%, following a sharp drop for US stocks overnight after Federal Reserve meeting minutes suggested a quicker run of rate increases. Investors are also nervous about the sharp spike in Omicron cases. Cryp...

The ASX 200 plummeted ~2.7% today, with a huge 6% selloff in the Tech sector weighing heavily on the index. All eleven sectors were in the red, following falls in Wall Street overnight that saw tech heavy Nasdaq slipping by 3.3%. Recent inv...

The Imugene Limited (ASX: IMU) share price is sliding in negative territory today despite a positive company update. At the time of writing, the immuno-oncology company’s shares are down 7.18% trading at 36 cents. It’s worth noting that Im...

Imugene (IMU) receives a South Korea patent grant for its HER-Vaxx Immunotherapy The patent will protect the composition and method of the product to 2036 Importantly, South Korea is a selected country to conduct the nextHERIZON Phase 2 cl...

Imugene’s HER-Vaxx candidate is in development for the HER-2 positive gastric cancer market, a type of stomach cancer with increased levels of a growth-promoting protein known as HER-2.

2021 came with many ups and downs, both on and off the market, but these 5 ASX shares weathered the storm to come out on top. We’ve taken a look at the All Ordinaries Index (ASX: XAO) – the index often used to gauge the market’s performanc...

On 05 January 2022, the equity market of Australia closed in red as healthcare sector witnessed selling pressure during the session. On the same day, ASX Midcap50 fell by 0.63% and ASX 300 was down by 0.32%. ASX All Ordinaries moved down by...

The Pro Medicus Limited (ASX: PME) share price sunk almost 10% on Wednesday despite no news being released from the company for more than a month. At market close, the Pro Medicus share price was down 9.69% to $56.95 apiece. It may be pa...

Highlights Australian shares dropped 0.3% to 7565.8 as heavy losses by healthcare and technology stocks weighed on the market. Investors across the globe are worried about interest rates increases and a spike in Omicron cases. The glo...

Australian stocks flirted with record levels before fading to their second loss in nine sessions as the seasonal Santa rally flagged. The S&P/ASX 200 peaked 13 points short of an all-time high in the first ten minutes of trade, then...

After lifting 2% yesterday, the ASX 200 retreated 0.3% today driven by a selloff in tech stocks. The local index opened higher in the morning, inching closer to its all time high before losing momentum after the mid session break. The tech...

The S&P/ASX 200 climbed to within 13 points of a record before turning lower as the Santa rally lost momentum.   The benchmark hit 7620.2 in early trade, then faded to a mid-session deficit of 21 points or 0.27 per cent. The broader...

Today, the S&P/ASX 200 Index (ASX: XJO) cemented its second-highest level on record as it kicked off the New Year with a bang. At the end of the session, the benchmark index finished 1.95% higher at 7,589.8 points. ASX investors were...

The first trading day of 2022 saw the ASX 200 surging by 2% to its highest level since August. All eleven sectors were in the green, with the Energy sector rising by more than 3.4, and Mining up 2.2%. The Energy sector was buoyed by coal st...

The first session of 2022 delivered the share market’s strongest advance in more than a year. The S&P/ASX 200 jumped 145 points or 1.95 per cent to its biggest gain since November 2020. All 11 sectors advanced. Macquarie Group bec...

The benchmark ASX 200 was up by 2% on the first day of trading in 2022. The ASX Emerging Companies Index (XEC) also rose in step, up by 1.6%. All eleven ASX sectors finished higher, with the energy and mining sectors leading the pack. In en...

The share market flew to a four-month high after Wall Street ended its first session of 2022 at a record. The S&P/ASX 200 surged 107 points or 1.44 per cent by mid-session. The rally eclipsed Friday’s 69-point end-of-year profit-taki...

The Imugene Limited (ASX: IMU) share price is climbing today following a development in the company’s latest clinical trial. The biotech company announced it had completed another leg in its trial for the treatment of lung cancer. It has...

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

The ASX 200 Health Index (XHJ) is trading higher by 0.30% at the time of writing, compared to the broader index which is also up by 0.87%. Imugene (ASX:IMU) is up by 8% this morning, after confirming that its immunotherapy candidate, PD1-Va...

Imugene (IMU) has completed the Phase 1a monotherapy dose escalation of PD1-Vaxx and will now go on to the combination dose escalation The PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer The tria...

“Our Phase 1a trial has been open 12 months and I’m pleased with both the pace of development and the early responses seen. It’s particularly gratifying to have followed a patient in the trial for over 12 months where their tumour burden ha...

It was the last full trading session for the ASX in 2021, and the local benchmark index closed flattish, just 0.04% higher at 7,512. The move followed S&P 500’s 70th record close overnight, with the Dow Jones also hovering at all time h...

The Santa rally overcame a mid-session wobble to deliver investors a sixth straight rise and a 16-week closing high on the last full trading session of 2021. The S&P/ASX 200 rallied in the final hour to a slender gain of 3.6 points o...